A universal epitope-based influenza vaccine and its efficacy against H5N1. (Q39988803)

16 September 2017

A universal epitope-based influenza vaccine and its efficacy against H5N1. (English)

1 reference

16 September 2017

1 reference

1 reference

Y Adar

1

1 reference

16 September 2017

Y Singer

2

1 reference

16 September 2017

R Levi

3

1 reference

16 September 2017

E Tzehoval

4

1 reference

16 September 2017

S Perk

5

1 reference

16 September 2017

C Banet-Noach

6

1 reference

16 September 2017

S Nagar

7

1 reference

16 September 2017

R Arnon

8

1 reference

16 September 2017

T Ben-Yedidia

9

1 reference

16 September 2017

language of work or name

English

0 references

publication date

13 February 2009

1 reference

16 September 2017

1 reference

16 September 2017

27

1 reference

16 September 2017

15

1 reference

16 September 2017

2099-2107

1 reference

The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality

16 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Design of peptide and polypeptide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Peptide vaccines against hepatitis B virus: from animal model to human studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Efficacy of anti-influenza peptide vaccine in aged mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Aromatic-dependent salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Rational design of Salmonella-based vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Genetic analysis of nonstructural genes (NS1 and NS2) of H9N2 and H5N1 viruses recently isolated in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Enu mouse mutagenesis: generation of mouse mutants with aberrant plasma IgE levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Current status of short synthetic peptides as vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Toll-like receptors in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Interleukin-18 secretion and Th1-like cytokine responses in human peripheral blood mononuclear cells under the influence of the toll-like receptor-5 ligand flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Functionally distinct T cells in three compartments of the respiratory tract after influenza virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Nonclassical HLA-G molecules are classical peptide presenters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Intranasal Influenza Vaccine in a Working Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Immune responses to epitopes inserted in Salmonella flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

A synthetic vaccine against influenza with built-in adjuvanticity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

Mapping T cell recognition: the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.011

10.1016/J.VACCINE.2009.02.011

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference